Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard.

J Lab Clin Med 1969;736:901–8. 16. Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 1991;66: 501–3. 17. von Schnakenburg C, Byrd DJ, Latta K, Reusz GS, Graf D, Brodehl J. Determination of oxalate excretion in spot urines of healthy children by ion chromatography. Eur J Clin Chem Clin Biochem 1994;32:27–9. 18. Detry O, Honore P, DeRoover A, Trimeche M, Demoulin JC, Beaujean M, et al. Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation. Transplant Int 2002;15:50–2. 19. Johnson JS, Short AK, Hutchison A, Parrott NR, Roberts IS. Small intestinal infarction: a fatal complication of systemic oxalosis. J Clin Pathol 2000;53: 720–1. 20. Marconi V, Mofid MZ, McCall C, Eckman I, Nousari HC. Primary hyperoxaluria: report of a patient with livedo reticularis and digital infarcts. J Am Acad Dermatol 2002;46:S16–8. 21. Boer P, van Leersum L, Hene RJ, Mees EJ. Plasma oxalate concentration in chronic renal disease. Am J Kidney Dis 1984;4:118–22. 22. Hylander E, Jarnum S, Nielsen K. Calcium treatment of enteric hyperoxaluria after jejunoileal bypass for morbid obesity. Scand J Gastroenterol 1980;15: 349–52. 23. Canos HJ, Hogg GA, Jeffery JR. Oxalate nephropathy due to gastrointestinal disorders. Can Med Assoc J 1981;124:729–33. 24. Drenick EJ, Stanley TM, Border WA, Zawada ET, Dornfeld LP, Upham T, et al. Renal damage with intestinal bypass. Ann Intern Med 1978;89:594–9. 25. McLeod RS, Churchill DN. Urolithiasis complicating inflammatory bowel disease. J Urol 1992;148:974–8. 26. Hassan I, Juncos LA, Milliner DS, Sarmiento JM, Sarr MG. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001;76:758–60.